Literature DB >> 25568765

Moderate hemoptysis caused by hughes-stovin syndrome.

Sahar El Aoud1, Faten Frikha1, Mouna Snoussi1, Zouhir Bahloul1.   

Abstract

Hughes and Stovin first reported a syndrome consisting of multiple pulmonary artery aneurysms and venous thrombosis in 1959. Here, we encountered a 42-year old woman who had hemoptysis revealing a Hughes-Stovin syndrome. Helical computed tomography showed multiple pulmonary artery aneurysms with pulmonary thromboembolism. The patient was treated with steroid therapy, cyclophosphamide and anticoagulation with a good response.

Entities:  

Keywords:  Hughes-Stovin syndrome; aneurysms; thrombosis

Year:  2014        PMID: 25568765      PMCID: PMC4274483          DOI: 10.4081/cp.2014.647

Source DB:  PubMed          Journal:  Clin Pract        ISSN: 2039-7275


Introduction

Hughes-Stovin syndrome (HSS) is an exceedingly rare disorder of unknown etiology. It is characterized by the combination of multiple pulmonary artery aneurysms (PAA) and deep venous thrombosis often involving the vena cava.[1-3] Many investigators consider it as an incomplete form of Behçet disease (BD). PAA sometimes results in hemoptysis and/or hemosputum. We present a case of a 42-year old woman having hemoptysis with multiple pulmonary artery aneurysms, unusual pulmonary arterial embolism, and oral ulcers.

Case Report

A 42-year old woman, with previously healthy status, was admitted to our internal department for fever, weakness, dyspnea and iterative hemoptoic sputums. Her fever began 2 months previously and showed an irregular pattern, not responsive to antipyretic medications. Minor hemoptysis began and increased gradually in 1 week’s duration before her hospitalization. She denied taking any drug that might predispose to bleeding. She had been suffering from oral aphthous ulcers for 5 years ago. There was no history of genital ulcerations, arthralgias, skin rash, or ocular disease suggestive of BD. The patient was febrile. She had a blood pressure of 130/80 mmHg, a pulse of 120 beats/min and a respiratory rate of 18 breaths/min. Physical examination revealed also oral aphthous ulceration but no genital scars due to healed ulcers. Ophthalmological exam was normal. There were no suggestive signs for deep venous thrombosis. Breath sounds were diminished over the left anterior and lateral areas of the chest, auscultation revealed inspiratory crackles. The pathergy test was negative. Laboratory analysis showed a white blood cells count at 31,000 cells/mL with 85% neutrophils, a hemoglobin value at 10.8 g/dL, and a platelet count at 570,000 cells/mL. The erythrocyte sedimentation rate was over 111 mm/hour and the C-reactive protein was at 30 mg/L. Creatinine, electrolyte levels, liver tests, and coagulation studies were within normal range. An arterial blood gas determination performed showed a PaO2 of 111 mmHg, PaCO2 of 53 mmHg, and a pH of 7.34. The admission chest radiograph demonstrated bilateral opacities with different diameter sizes in the lower lobes. A contrast enhanced computed tomography (CT) of the thorax disclosed multiple pulmonary aneurysms with mural thrombosis filling from the upper lobe pulmonary artery branch, the largest was 9x8x7 mm of diameter, and thromboembolism of the left pulmonary artery (Figure 1).
Figure 1.

A and B) Contrast enhanced computed tomography of the thorax axial section showing multiple pulmonary aneurysms (arrows in A and B) with mural thrombosis filling from the upper lobe pulmonary artery branc.

All serologic markers were negative and no microorganisms could be identified from her blood, urine, and sputum cultures. The hemagglutination test for Treponema pallidum, and tests for human immunodeficiency virus, hepatitis B surface antigen, tuberculosis, Rickettsia, Aspergillus, and Candida albicans were all negative. Coagulation studies were normal (prothrombin time, partial thromboplastin time, antithrombin III, protein C activity, protein S activity, activated protein C resistance ratio). Immunological analysis including antinuclear antibodies, rheumatoid factor and antineutrophilic cytoplasmic antibodies were also within the referential range. Human lymphocyte antigen B5 was also negative. Thereafter, she did not fulfill the diagnostic criteria of the complete BD. Finally, a rare diagnosis of systemic vasculitis, HSS was made on the basis of multiple pulmonary artery aneurysms and pulmonary thrombi in such a young patient. The patient was treated with low-molecular-weight heparin, the appropriate oral anticoagulant therapy (with optimal therapeutic international normalized ratio range between 2 and 3). A high-dose regimen of prednisone (1 mg/kg/day) and monthly bolus of cyclophosphamide were started (1 g/month for a total of 12 bolus). Coil embolization of the aneurysm was not performed because there was no massive hemoptysis. Thenceforward, she was afebrile with eupneic respiratory rythm and no further hemoptysis. Two months later, in the control chest CT, the aneurysms except the ones at the lower lobe were all regressed with disappearance of aneurysm mural thrombosis (Figure 2).
Figure 2.

A and B) Contrast enhanced computed tomography. Control after 2 months of treatment: the aneurysms except the ones at the lower lobe were all regressed with disappearance of aneurysm mural thrombosis.

The complaint was getting worse in a month before, accompanied by 1 episode of fever. Chest examination showed midscapular crackles. Chest-X-ray (Figure 3) and CT scan (Figure 4) revealed a left midzone cavitary lesion. Aspergillus antibodies and antigens were negative. Sputum smear for acid-fast bacilli (AFB) was negative so was the culture of sputum for AFB.
Figure 3.

Chest-X-ray revealing a left midzone cavitary lesion (arrow).

Figure 4.

A and B) Computed tomography scans of thorax showing a left midzone cavitary lesion (arrow).

The culture-sensitivity examination of bronchoalveolar lavage was positive for C. albicans. The patient was diagnosed with pulmonary candidiasis. She received treatments with cefotaxim 3 g once daily, fluconazole 200 mg per day for 14 days with a good response. After one year of follow up and after a total of 12 bolus of cyclophosphamid, the patient is going well, without a recurrence of hemoptysis.

Discussion

In 1959, Hughes and Stovin reported four cases of deep venous thrombosis and multiple segmental pulmonary artery aneurysms.[1] Since then, this association of multiple pulmonary aneurysms and peripheral venous thrombosis has been named Hughes-Stovin syndrome[4] and several cases have been published.[2-6] There have been less than 50 published cases of HSS described in English medical literature so far.[7] It usually affects the young adult aged from 12 to 48 years and holds a strong predilection for the male gender[4,8,9] with only 6 cases describing women.[7,10-13] We report a case of a 42 year-old woman with the HSS in whom multiple pulmonary arterial aneurysms with an unusual pulmonary arterial embolism were found. To our knowledge, our patient is the seventh woman presenting this disease. Etiopathogenesis of HSS remains largely obscure and a systemic vasculitis has been suggested.[14] Septic embolisms, angiodysplasia of bronchial arteries, are another debatable hypothesis to account for the vascular changes.[7,15] Actually, weakening of the arterial wall from the subsequent inflammation is the likely mechanism.[3] Being an extremely rare disease, there are no formally described diagnostic criteria or pathognomonic laboratory investigations for this syndrome. Generally, the syndrome is characterized by the association of multiple pulmonary and/or bronchial aneurysms and thrombophlebitis. Nearly 25% of patients with HSS develop vascular thromboembolism, arterial aneurysms, and arterial and venous occlusions with nonspecific vasculitis. The vascular lesions are arterial in 7%, venous in 25%, and both in 68% of reported cases.[10] Reports indicate that pulmonary lesions and deep venous thrombosis of the lower extremities are the most frequent findings.[10] Aneurysms may be single or multiple, unilateral or bilateral. It is rarely multiple or bilateral. Aneurysms at other anatomic locations (iliac, femoral, popliteal, carotid and hepatic arteries) have also been described in HSS. Peripheral venous thrombosis may affect vena cavae, jugular veins, iliac veins, femoral veins, hepatic veins, cerebral venous sinuses or even the cardiac chambers.[15] Our patient has multiple pulmonary artery aneurysms associated with embolism of the left pulmonary artery without peripheral deep vein thrombosis. The typical presentation of HSS involves in 3 phases: a first stage involving symptoms of thrombophlebitis, a second stage consisting of formation and enlargement of pulmonary aneurysms, and a third stage of aneurysmal rupture that triggers massive hemoptysis, leading to death.[9] The main clinical features of the syndrome can be non-specific including cough, dyspnea and fever. Hemoptysis may be a late sequela of disease progression, thus making early diagnosis a challenge.[5] Chest radiography may reveal round opacities and hilar enlargement. Helical computed tomography (HCT) and magnetic resonance imaging have been reported as non-invasive method useful for the diagnosis of PAA. They may demonstrate high quality vascular images with more sensitivity of HCT in the detection of small aneurysms.[5] Pulmonary angiography should be avoided because of the potential of aneurysm formation. Two types of vasculitis have commonly been associated with PAA: BD and HSS. So that, the main differential diagnosis of the HSS is BD; a multisystem disorder, that at onset, may present with PAA, which is scarce; usually around 1.5%.[16] Several authors suggested that HSS is a variant or an incomplete presentation of BD owing to their similar clinical, radiological and histopathological findings.[15] In fact, HSS might be a cardiovascular manifestation of BD or the incomplete type of BD (isolated pulmonary presentation of BD with the inflammatory vascular component but lacking some of the other clinical manifestations like oral and genital ulceration, skin lesions, and uveitis). On the other hand, arterial involvement in BD was expressed by aneurysms that can involve all arterial territories with a preference for the pulmonary arteries (HSS).[11,17] Takayasu arteritis can also involve the pulmonary arteries; however, more commonly, it produces pulmonary artery narrowing and occlusion rather than dilation. There are also reports of mycotic pulmonary artery aneurysms resulting from Mycobacterium tuberculosis, and from fungi, such as Mucormycosis, Aspergillus, and Candida.[15] Therefore, these infectious etiologies should be eliminated before thinking about systemic diseases such as the case of our patient. Owing to the lack of controlled trials, there are no standard treatment guidelines for HSS and various treatment modalities have been described in the management of this disease. These include immunosuppression with systemic corticosteroid and cytotoxic agents (cyclophosphamide),[7] used most commonly in the treatment of the early stages of the disease. This therapy confers clinical improvement, stabilization and even regression of small pulmonary artery aneurysms in most patients.[5] Anticoagulation is generally contraindicated due to an increased risk of fatal hemorrhage. However, it may be employed with great vigilance in a few carefully evaluated circumstances where the benefits are believed to significantly outweigh the risks.[15] A therapeutic dilemma is often posed in using anticoagulants if pulmonary embolism is present. Anticoagulation may prevent the progression of pulmonary embolism and resolve vein thrombi. Our patient benefited of anticoagulation because of thromboembolism of the left pulmonary artery and the aneurysm mural thrombosis. For patients with extensive, bilateral multifocal aneurysms and/or severe or recurrent hemoptysis arterial embolization has been suggested as the treatment modality choice.[7,15] Surgical treatment (lobectomy or pneumonectomy) is reserved for some cases complicated by massive hemoptysis due to a large pulmonary aneurysm but with associated high morbidity and mortality.[5] Our patient described in this report, was treated with immunosuppression with both cyclophosphamide and prednisone with favorable outcome. She has remained free of pulmonary artery aneurysms and hemoptysis after 12 months of follow-up.

Conclusions

HSS is a rare but grave clinical entity and has not been extensively studied so far. The cause of this entity is currently unknown. Our patient presented a particular clinical presentation of HSS, which should be kept in mind in the differential diagnosis of pulmonary involvement of BD. It seems that the most convenient method of imaging is angio-CT scan. Early detection and treatment is mandatory to save the patient’s life.
  16 in total

1.  Segmental pulmonary artery aneurysms with peripheral venous thrombosis.

Authors:  J P HUGHES; P G STOVIN
Journal:  Br J Dis Chest       Date:  1959-01

2.  Successful multimodality treatment of a young woman with Hughes-Stovin syndrome.

Authors:  Nicole E Curci; Thomas V Bilfinger
Journal:  Am Surg       Date:  2012-05       Impact factor: 0.688

3.  CT angiography of pulmonary artery aneurysms in Hughes-Stovin syndrome.

Authors:  Eric S Ketchum; Roham T Zamanian; Dominik Fleischmann
Journal:  AJR Am J Roentgenol       Date:  2005-08       Impact factor: 3.959

4.  Images in cardiovascular medicine. Large pulmonary artery aneurysm rupture in Hughes-Stovin syndrome: multidetector computed tomography pattern and endovascular treatment.

Authors:  Antoine Khalil; Antoine Parrot; Muriel Fartoukh; Claude Marsault; Marie-France Carette
Journal:  Circulation       Date:  2006-09-05       Impact factor: 29.690

5.  Successful cyclophosphamide therapy with complete resolution of pulmonary artery aneurysm in Hughes-Stovin syndrome patient.

Authors:  Jaejoon Lee; Jung-Won Noh; Ji Won Hwang; Hyungjin Kim; Joong Kyong Ahn; Eun-Mi Koh; Hoon-Suk Cha
Journal:  Clin Rheumatol       Date:  2008-07-01       Impact factor: 2.980

6.  Use of an amplatzer vascular plug in embolization of a pulmonary artery aneurysm in a case of hughes-stovin syndrome: a case report.

Authors:  Vasileios D Tzilalis; Georgios Vourliotakis; Ioannis A Tsironis; Vasileios D Tsiligiris; Elias N Brountzos
Journal:  J Med Case Rep       Date:  2011-09-01

7.  Is Hughes-Stovin syndrome a particular expression of Behçet's disease?

Authors:  M F François
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

8.  Hughes-Stovin syndrome. Report of a female autopsy case and review of the literature.

Authors:  M Kinjo; K Tanaka; S Ishimaru; N Shigematsu; K Sugiyama
Journal:  Acta Pathol Jpn       Date:  1978-03

Review 9.  Hughes-Stovin syndrome.

Authors:  Umair Khalid; Taimur Saleem
Journal:  Orphanet J Rare Dis       Date:  2011-04-13       Impact factor: 4.123

10.  Hughes-Stovin syndrome: a case report and review of the literature.

Authors:  Athanasios N Chalazonitis; Stefanos B Lachanis; Panagiotis Mitseas; Panagiotis Argyriou; Joannie Tzovara; Petros Porfyrides; Evangelia Sotiropoulou; Nikolaos Ptohis
Journal:  Cases J       Date:  2009-01-29
View more
  3 in total

1.  Recurrent Haemoptysis Revealing Hughes-Stovin Syndrome.

Authors:  Nedia Moussa; Tasnim Znegui; Mouna Snoussi; Rahma Gargouri; Zouhaier Bahloul; Sourour Abid; Samy Kammoun
Journal:  Eur J Case Rep Intern Med       Date:  2021-10-05

2.  Hughes-Stovin syndrome: an unusual cause of pulmonary artery aneurysms.

Authors:  Bruno Niemeyer de Freitas Ribeiro; Renato Niemeyer Ribeiro; Gláucia Zanetti; Edson Marchiori
Journal:  Radiol Bras       Date:  2016 May-Jun

3.  Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide-a report by the HSS International Study Group.

Authors:  Yasser Emad; Yasser Ragab; Cal Robinson; Sonia Pankl; Pablo Young; Marianna Fabi; Parag Bawaskar; Ossama Ibrahim; Doruk Erkan; Bhupen Barman; Jasna Tekavec-Trkanjec; Balakrishnan Jayakrishnan; Michael Kindermann; Melek Kechida; Aurelien Guffroy; Rafael S Silva; Faten Frikha; Alaa Abou-Zeid; Maged Hassan; Harrison W Farber; Mohamed H Abdelbary; Leticia Tornes; Jason Margolesky; Nashwa El-Shaarawy; Sami Bennji; Manoj Kumar Agarwala; Ahmed Saad; Taoufik Amezyane; Sergio Ghirardo; Vitor Cruz; Bruno Niemeyer; Khalfan Al-Zeedy; Hamdan Al-Jahdali; Natalia Jaramillo; Serkan Demirkan; Issam Kably; Jung Tae Kim; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2021-09-17       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.